Specifically, in an OVA-induced murine asthma model, intranasal treatment with a polyclonal rabbit anti-ALCAM antibody at the time of OVA challenge reduced allergic symptoms, such as the leukocyte count and Th2 cytokine (i.e., IL-4, IL-5, and IL-13) levels in BAL fluid [10]. This evidence concerns the gene IL5 and asthma.